Similar articles

• Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia.

  Dusetzina SB, Winn AN, Abel GA, Huskamp HA, Keating NL. Dusetzina SB, et al. J Clin Oncol. 2014 Feb 1;32(4):306-11. doi: 10.1200/JCO.2013.52.9123. Epub 2013 Dec 23. J Clin Oncol. 2014. PMID: 24366936
• The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia.

  Eskazan AE, Elverdi T, Yalniz FF, Salihoglu A, Ar MC, Ongoren Aydin S, Baslar Z, Aydin Y, Tuzuner N, Ozbek U, Soysal T. Eskazan AE, et al. Leuk Lymphoma. 2014 Dec;55(12):2935-7. doi: 10.3109/10428194.2014.905774. Epub 2014 May 6. Leuk Lymphoma. 2014. PMID: 24650055 No abstract available.
• With targeted drugs, chronic myelogenous leukemia therapy may follow HIV's model.

  Tuma RS. Tuma RS. J Natl Cancer Inst. 2007 Feb 7;99(3):192-4. doi: 10.1093/jnci/djk073. J Natl Cancer Inst. 2007. PMID: 17284712 No abstract available.
• Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia.

  Taylor MJ, Scuffham PA. Taylor MJ, et al. Expert Rev Pharmacoecon Outcomes Res. 2009 Apr;9(2):117-21. doi: 10.1586/erp.09.1. Expert Rev Pharmacoecon Outcomes Res. 2009. PMID: 19402798 Review.
• Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU.

  Conti RM, Padula WV, Larson RA. Conti RM, et al. Ann Hematol. 2015 Apr;94 Suppl 2(0 2):S249-57. doi: 10.1007/s00277-015-2319-x. Epub 2015 Mar 27. Ann Hematol. 2015. PMID: 25814091 Free PMC article. Review.